21 September 2009

Minster Pharmaceuticals plc

('Minster' or the 'Company')

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that Robert Aubrey, an Executive Director, will step down from executive responsibilities with effect from 30 September 2009 to become a Non-executive Director.

Mr Aubrey has served the Company in an executive capacity for a total of 8 years. He is stepping down from executive responsibilities following the successful completion of the transfer of finance and internal control procedures to Karl Keegan, Chief Financial Officer, who was appointed in April 2009.

John Russell, Minster's Chairman, said: 'Bob has made an impressive contribution to Minster during his eight years as an executive. We are particularly pleased that he has agreed to continue to serve the Company as a Non-executive Director, through which we can continue to benefit from his wise counsel.'

For further information:

Minster Pharmaceuticals plc                             Tel: +44 (0) 1799 506623
John Russell, Chairman and Interim CEO 
Karl Keegan, Chief Financial Officer                    Tel: +44 (0) 20 7936 9921
 
Buchanan Communications                               Tel: +44 (0) 20 7466 5000
Mark Court / Catherine Breen 
 
Nomura Code Securities Limited                         Tel: +44 (0) 20 7776 1200
Chris Collins / Richard Potts  

Notes for editors:

About Minster Pharmaceuticals plc

Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.

Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com